This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
International Agency for Research on Cancer. World health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 20012. Lung cancer fact sheet. [Citated 2016 Jun 15]. Available at http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=lung.International Agency for Research on Cancer. World health OrganizationGLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 20012Lung cancer fact sheet. [Citated 2016 Jun 15]. Available athttp://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=lungSearch in Google Scholar
Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database survey. J Thorac Oncol 2010; 5: 29-33. 10.1097/JTO.0b013e3181c5920cMorgenszternDNgSHGaoFGovindanR.Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database surveyJ Thorac Oncol20105293310.1097/JTO.0b013e3181c5920c19952801Open DOISearch in Google Scholar
Debevec L, Jerič T, Kovač V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53. 10.2478/v10019-009-0008-xDebevecLJeričTKovačVBitencMSokM.Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006Radiol Oncol200943475310.2478/v10019-009-0008-xOpen DOISearch in Google Scholar
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al.SEER cancer statistics review, 1975-2013. Bethesda: National Cancer Institute. [Citated 2016 Sept 04]. Available at http://seer.cancer.gov/csr/1975_2013/HowladerNNooneAMKrapchoMMillerDBishopKAltekruseSFet al.SEER cancer statistics review 1975-2013Bethesda: National Cancer Institute[Citated 2016 Sept 04]Available athttp://seer.cancer.gov/csr/1975_2013/Search in Google Scholar
Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, et al. Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med 2013; 6: 25-36. 10.2147/PGPM.S26058SechlerMCizmicADAvasaralaSVan ScoykMBrzezinskiCKelleyNet al.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategiesPharmgenomics Pers Med20136253610.2147/PGPM.S26058365646423690695Open DOISearch in Google Scholar
Zwitter M, Stanic K, Rajer M, Kern I, Vrankar M, Edelbaher N, Kovac V. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiol Oncol 2014; 48: 361-8. 10.2478/raon-2014-0038ZwitterMStanicKRajerMKernIVrankarMEdelbaherNKovacV.Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutationsRadiol Oncol201448361810.2478/raon-2014-0038423055625435849Open DOISearch in Google Scholar
Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 2016; 9: 3711-26. 10.2147/OTT.S106399WangJWangBChuHYaoY.Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsOnco Targets Ther2016937112610.2147/OTT.S106399492276527382309Open DOISearch in Google Scholar
Ward CW, Garrett TP, McKern NM, Lou M, Cosgrove LJ, Sparrow LG, et al. The three dimensional structure of the type I insulin-like growth factor receptor. Mol Pathol 2001; 54: 125-32.WardCWGarrettTPMcKernNMLouMCosgroveLJSparrowLGet al.The three dimensional structure of the type I insulin-like growth factor receptorMol Pathol2001541253210.1136/mp.54.3.125118704911376122Search in Google Scholar
Blakesley VA, Stannard BS, Kalebic T, Helman LJ, LeRoith D. Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 1997; 152: 339-44.BlakesleyVAStannardBSKalebicTHelmanLJLeRoithD.Role of the IGF-I receptor in mutagenesis and tumor promotionJ Endocrinol19971523394410.1677/joe.0.15203399071953Search in Google Scholar
Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquières G, Wolf-Kümmeth S, et al. Hyperactivation of the insulin-like growth factor receptor I signalling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009; 69: 2996-3003. 10.1158/0008-5472.CAN-08-3153EcksteinNServanKHildebrandtBPolitzAvon JonquièresGWolf-KümmethSet al.Hyperactivation of the insulin-like growth factor receptor I signalling pathway is an essential event for cisplatin resistance of ovarian cancer cellsCancer Res2009692996300310.1158/0008-5472.CAN-08-315319318572Open DOISearch in Google Scholar
Huang F, Xu LA, Khambata-Ford S. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer. Clin Cancer Res 2012; 18: 1156-66. 10.1158/1078-0432.CCR-11-1135HuangFXuLAKhambata-FordS.Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancerClin Cancer Res20121811566610.1158/1078-0432.CCR-11-113522294722Open DOISearch in Google Scholar
Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, et al. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 2009; 8: 1448-59. 10.1158/1535-7163.MCT-09-0101YuenJSAkkayaEWangYTakiguchiMPeakSSullivanMet al.Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancerMol Cancer Ther2009814485910.1158/1535-7163.MCT-09-010119509240Open DOISearch in Google Scholar
Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T. The insulinlike growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. Int J Cancer 2014; 135: 1002-6. 10.1002/ijc.28737SudaKMizuuchiHSatoKTakemotoTIwasakiTMitsudomiT.The insulinlike growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptorInt J Cancer20141351002610.1002/ijc.2873724458568Open DOISearch in Google Scholar
Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, et al. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in nonsmall cell lung cancer patients harboring activating EGFR mutations. Lung Cancer 2015; 87: 311-7. 10.1016/j.lungcan.2015.01.004YeoCDParkKHParkCKLeeSHKimSJYoonHKet al.Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in nonsmall cell lung cancer patients harboring activating EGFR mutationsLung Cancer201587311710.1016/j.lungcan.2015.01.00425617986Open DOISearch in Google Scholar
Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, et al. Rationale for co-targeting IGF1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014; 20: 1027-34. 10.1038/nm.3667LovlyCMMcDonaldNTChenHOrtiz-CuaranSHeukampLCYanYet al.Rationale for co-targeting IGF1R and ALK in ALK fusion-positive lung cancerNat Med20142010273410.1038/nm.3667415940725173427Open DOISearch in Google Scholar
Beckwith H, Yee D. Minireview: Were the IGF signaling inhibitors all bad? Mol Endocrinol 2015; 29: 1549-57. 10.1210/me.2015-1157.BeckwithHYeeD.Minireview: Were the IGF signaling inhibitors all bad?Mol Endocrinol20152915495710.1210/me.2015-1157Open DOISearch in Google Scholar
Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, et al. Insulinlike growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2012; 132: 131-42. 10.1007/s10549-011-1529-8YerushalmiRGelmonKALeungSGaoDCheangMPollakMet al.Insulinlike growth factor receptor (IGF-1R) in breast cancer subtypesBreast Cancer Res Treat20121321314210.1007/s10549-011-1529-821574055Open DOISearch in Google Scholar
Mountzios G, Aivazi D, Kostopoulos I, Kourea HP, Kouvatseas G, Timotheadou E, et al. Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. PLoS One 2014; 9: e91407. 10.1371/journal.pone.0091407MountziosGAivaziDKostopoulosIKoureaHPKouvatseasGTimotheadouEet al.Differential expression of the insulin-like growth factor receptor among early breast cancer subtypesPLoS One20149e9140710.1371/journal.pone.0091407395667224637962Open DOISearch in Google Scholar
Bahhnassy A, Mohanad M, Shaarawy S, Ismail MF, El-Bastawisy A, Ashmawy AM, et al. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer. Mol Med Rep 2015; 12: 851-64. 10.3892/mmr.2015.3560BahhnassyAMohanadMShaarawySIsmailMFEl-BastawisyAAshmawyAMet al.Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancerMol Med Rep2015128516410.3892/mmr.2015.3560443887825824321Open DOISearch in Google Scholar
Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, et al. Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One 2013; 8: e54048. 10.1371/journal.pone.0054048MountziosGKostopoulosIKotoulaVSfakianakiIFountzilasEMarkouKet al.Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancerPLoS One20138e5404810.1371/journal.pone.0054048355475523365645Open DOISearch in Google Scholar
Huang Y-F, Shen M-R, Hsu K-F, Cheng Y-M, Chou C-Y. Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br J Cancer 2008; 99: 1096-102. 10.1038/sj.bjc.6604661HuangY-FShenM-RHsuK-FChengY-MChouC-YClinical implications of insulin-like growth factor 1 system in early-stage cervical cancerBr J Cancer200899109610210.1038/sj.bjc.6604661256706318781172Open DOISearch in Google Scholar
Hirakawa T, Yashiro M, Murata A, Hirata K, Kimura K, Amano R, et al. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer. 2013; 13: 392. 10.1186/1471-2407-13-392HirakawaTYashiroMMurataAHirataKKimuraKAmanoRet al.IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancerBMC Cancer20131339210.1186/1471-2407-13-392376510023962053Open DOISearch in Google Scholar
Numata K, Oshima T, Sakamaki K, Yoshihara K, Aoyama T, Hayashi T, et al. Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1. J Cancer Res Clin Oncol 2016; 142: 415-22. 10.1007/s00432-015-2039-6NumataKOshimaTSakamakiKYoshiharaKAoyamaTHayashiTet al.Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1J Cancer Res Clin Oncol20161424152210.1007/s00432-015-2039-626337161Open DOISearch in Google Scholar
Sichani MM, Yazdi FS, Moghaddam NA, Chehrei A, Kabiri M, Naeimi A, et al. Prognostic value of insulin-like growth factor-I receptor expression in renal cell carcinoma. Saudi J Kidney Dis Transpl 2010; 21: 69-74.SichaniMMYazdiFSMoghaddamNAChehreiAKabiriMNaeimiAet al.Prognostic value of insulin-like growth factor-I receptor expression in renal cell carcinomaSaudi J Kidney Dis Transpl2010216974Search in Google Scholar
Gonzalez-Roibon N, Kim JJ, Faraj SF, Chaux A, Bezerra SM, Munari E, et al. Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelialcarcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy. Urology 2014; 83: 1444. e1-6. 10.1016/j.urology.2014.01.028Gonzalez-RoibonNKimJJFarajSFChauxABezerraSMMunariEet al.Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelialcarcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomyUrology2014831444e1610.1016/j.urology.2014.01.02824713135Open DOISearch in Google Scholar
Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, et al. Primary resistance to cetuximab therapy in EGFR FISHpositive colorectal cancer patients. Br J Cancer 2008; 99: 83-9. 10.1038/sj.bjc.6604439CappuzzoFVarella-GarciaMFinocchiaroGSkokanMGajapathySCarnaghiCet al.Primary resistance to cetuximab therapy in EGFR FISHpositive colorectal cancer patientsBr J Cancer20089983910.1038/sj.bjc.6604439245304118577988Open DOISearch in Google Scholar
Takahari D, Yamada Y, Okita N, T, Honda T, Hirashima Y, Matsubara J, et al. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 2009; 76: 42-8. 10.1159/000178164TakahariDYamadaYOkitaN THondaTHirashimaYMatsubaraJet al.Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancerOncology20097642810.1159/00017816419033715Open DOISearch in Google Scholar
Joehlin-Price AS, Stephens JA, Zhang J, Backes FJ, Cohn DE, Suarez AA. Endometrial cancer insulin-like growth factor 1 receptor (IGF1R) expression increases with body mass index and is associated with pathologic extent and prognosis. Cancer Epidemiol Biomarkers Prev 2016; 25: 438-45. 10.1158/1055-9965.EPI-15-1145Joehlin-PriceASStephensJAZhangJBackesFJCohnDESuarezAA.Endometrial cancer insulin-like growth factor 1 receptor (IGF1R) expression increases with body mass index and is associated with pathologic extent and prognosisCancer Epidemiol Biomarkers Prev2016254384510.1158/1055-9965.EPI-15-1145507596726682991Open DOISearch in Google Scholar
Peiró G, Lohse P, Mayr D, Diebold J. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome. Am J Clin Pathol 2003; 120: 78-85. 10.1309/C1KA-H1PR-L1UB-W798PeiróGLohsePMayrDDieboldJ.Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcomeAm J Clin Pathol2003120788510.1309/C1KA-H1PR-L1UB-W79812866376Open DOISearch in Google Scholar
Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010; 28: 2174-80. 10.1200/JCO.2009.24.6611DziadziuszkoRMerrickDTWittaSEMendozaADSzostakiewiczBSzymanowskaAet al.Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expressionJ Clin Oncol20102821748010.1200/JCO.2009.24.6611286043520351332Open DOISearch in Google Scholar
Lee CY, Jeon JH, Kim HJ, Shin DH, Roh TW, Ahn CM, et al. Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis. Korean J Intern Med 2008; 23: 116-20. 10.3904/kjim.2008.23.3.116LeeCYJeonJHKimHJShinDHRohTWAhnCMet al.Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysisKorean J Intern Med2008231162010.3904/kjim.2008.23.3.116268696118787363Open DOISearch in Google Scholar
Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009; 4: e7273. 10.1371/journal.pone.0007273GongYYaoEShenRGoelAArcilaMTeruya-FeldsteinJet al.High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)PLoS One20094e727310.1371/journal.pone.0007273275217119806209Open DOISearch in Google Scholar
Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 2010; 21: 562-7. 10.1093/annonc/mdp357CappuzzoFTalliniGFinocchiaroGWilsonRSLigorioCGiordanoLet al.Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patientsAnn Oncol201021562710.1093/annonc/mdp357336227119767315Open DOISearch in Google Scholar
Ning XH, Wang YZ, Bai CM, Li J. Clinical significance of insulin-like growth factor-1 receptor in platinum-based chemotherapy for non-small celllung cancer. [Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2010; 32: 366-70. 10.3881/j.issn.1000-503X.2010.04.002NingXHWangYZBaiCMLiJ.Clinical significance of insulin-like growth factor-1 receptor in platinum-based chemotherapy for non-small celllung cancer. [Chinese]Zhongguo Yi Xue Ke Xue Yuan Xue Bao2010323667010.3881/j.issn.1000-503X.2010.04.00220868591Open DOISearch in Google Scholar
Tsuta K, Mimae T, Nitta H, Yoshida A, Maeshima AM, Asamura H, et al. Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lungcarcinomas. Hum Pathol 2013; 44: 975-82. 10.1016/j.humpath.2012.09.002TsutaKMimaeTNittaHYoshidaAMaeshimaAMAsamuraHet al.Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lungcarcinomasHum Pathol2013449758210.1016/j.humpath.2012.09.00223266446Open DOISearch in Google Scholar
Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G, et al. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemother Pharmacol 2013; 71: 671-80. 10.1007/s00280-012-2056-yLudoviniVFlaccoABianconiFRagusaMVannucciJBellezzaGet al.Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patientsCancer Chemother Pharmacol2013716718010.1007/s00280-012-2056-y396313923314677Open DOISearch in Google Scholar
Zhang X, Sun J, Wang H, Lou Y, Zhang Y, Sha H, et al. IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance. Tumour Biol 2014; 35: 739-45. 10.1007/s13277-013-1100-9ZhangXSunJWangHLouYZhangYShaHet al.IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significanceTumour Biol2014357394510.1007/s13277-013-1100-923990442Open DOISearch in Google Scholar
Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, et al. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clin Lung Cancer 2014; 15: 58-66. 10.1016/j.cllc.2013.08.005GatelyKFordeLCuffeSCumminsRKayEWFeuerhakeFet al.High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancerClin Lung Cancer201415586610.1016/j.cllc.2013.08.00524210543Open DOISearch in Google Scholar
Tran TN, Selinger CI, Yu B, Ng CC, Kohonen-Corish MR, McCaughan B, et al. Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. J Clin Pathol 2014; 67: 985-91. 10.1136/jclinpath-2014-202347TranTNSelingerCIYuBNgCCKohonen-CorishMRMcCaughanBet al.Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancerJ Clin Pathol2014679859110.1136/jclinpath-2014-20234725118293Open DOISearch in Google Scholar
Nakagawa M, Uramoto H, Shimokawa H, Onitsuka T, Hanagiri T, Tanaka F. Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung. Exp Ther Med 2011; 2: 585-90. 10.3892/etm.2011.258NakagawaMUramotoHShimokawaHOnitsukaTHanagiriTTanakaF.Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lungExp Ther Med201125859010.3892/etm.2011.258344075222977544Open DOISearch in Google Scholar
Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, et al. Prognostic impact of insulin receptor expression on survival of patients with non small cell lung cancer. Cancer 2012; 118: 2454-65. 10.1002/cncr.26492KimJSKimESLiuDLeeJJSolisLBehrensCet al.Prognostic impact of insulin receptor expression on survival of patients with non small cell lung cancerCancer201211824546510.1002/cncr.26492329884321952750Open DOISearch in Google Scholar
Yamamoto T, Oshima T, Yoshihara K, Nishi T, Arai H, Inui K, et al. Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrixmetalloproteinase-7 in resected non-small cell lung cancer. Exp Ther Med 2012; 3: 797-802. 10.3892/etm.2012.493YamamotoTOshimaTYoshiharaKNishiTAraiHInuiKet al.Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrixmetalloproteinase-7 in resected non-small cell lung cancerExp Ther Med2012379780210.3892/etm.2012.493343855022969971Open DOISearch in Google Scholar
Xu C, Xie D, Yu SC, Yang XJ, He LR, Yang J, et al. β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res 2013; 73: 3181-9. 10.1158/0008-5472.CAN-12-4403XuCXieDYuSCYangXJHeLRYangJet al.β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinomaCancer Res2013733181910.1158/0008-5472.CAN-12-440323539445Open DOISearch in Google Scholar
Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006; 17: 1120-7. 10.1093/annonc/mdl077CappuzzoFToschiLTalliniGCeresoliGLDomenichiniIBartoliniSet al.Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinibAnn Oncol2006171120710.1093/annonc/mdl077Open DOISearch in Google Scholar
Kikuchi R, Sonobe M, Kobayashi M, Ishikawa M, Kitamura J, Nakayama E, et al. Expression of IGF1R is associated with tumor differentiation and survival in patients with lung adenocarcinoma. Ann Surg Oncol 2012; 19(Suppl 3): S412-20. 10.1245/s10434-011-1878-x.KikuchiRSonobeMKobayashiMIshikawaMKitamuraJNakayamaEet al.Expression of IGF1R is associated with tumor differentiation and survival in patients with lung adenocarcinomaAnn Surg Oncol201219(Suppl 3)S4122010.1245/s10434-011-1878-xOpen DOISearch in Google Scholar
Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, et al. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer. Clin Lung Cancer 2012; 13: 385-90. 10.1016/j.cllc.2011.11.009KimYHSumiyoshiSHashimotoSMasagoKTogashiYSakamoriYet al.Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancerClin Lung Cancer2012133859010.1016/j.cllc.2011.11.009Open DOISearch in Google Scholar
Park E, Park SY, Kim H, Sun PL, Jin Y, Cho SK, et al. Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma. J Pathol Transl Med 2015; 49: 382-8. 10.4132/jptm.2015.07.10ParkEParkSYKimHSunPLJinYChoSKet al.Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung AdenocarcinomaJ Pathol Transl Med201549382810.4132/jptm.2015.07.10Open DOISearch in Google Scholar
Zhao S, Qiu Z, He J, Li L, Li W. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis. IntJ Clin Exp Pathol 2014; 7: 6694-704.ZhaoSQiuZHeJLiLLiW.Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysisIntJ Clin Exp Pathol201476694704Search in Google Scholar
Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2: 48-53. 10.1038/ncponc0062RichardsonLCPollackLA.Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancerNat Clin Pract Oncol20052485310.1038/ncponc0062Open DOISearch in Google Scholar
Ding J, Tang J, Chen X, Men HT, Luo WX, Du Y, et al. Expression characteristics of proteins of the insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitus. Asian Pac J Cancer Prev 2013; 14: 5675-80.DingJTangJChenXMenHTLuoWXDuYet al.Expression characteristics of proteins of the insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitusAsian Pac J Cancer Prev20131456758010.7314/APJCP.2013.14.10.5675Search in Google Scholar
LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-37.LeRoithDRobertsCT JrThe insulin-like growth factor system and cancerCancer Lett20031951273710.1016/S0304-3835(03)00159-9Search in Google Scholar
Wang HS, Wang TH. Polycystic ovary syndrome (PCOS), insulin resistance and insulin-like growth factors (IGfs)/IGF-binding proteins (IGFBPs). Chang Gung Med J 2003; 26: 540-53.WangHSWangTH.Polycystic ovary syndrome (PCOS), insulin resistance and insulin-like growth factors (IGfs)/IGF-binding proteins (IGFBPs)Chang Gung Med J20032654053Search in Google Scholar
Zhou Y, Zhang X, Gu C, Xia J. Diabetes mellitus is associated with breast cancer: systematic review, meta-analysis, and in silico reproduction. Panminerva Med 2015; 57: 101-8.ZhouYZhangXGuCXiaJ.Diabetes mellitus is associated with breast cancer: systematic review, meta-analysis, and in silico reproductionPanminerva Med2015571018Search in Google Scholar
Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol 2011; 26: 863-76. 10.1007/s10654-011-9617-yJiangYBenQShenHLuWZhangYZhuJ.Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studiesEur J Epidemiol2011268637610.1007/s10654-011-9617-y21938478Open DOISearch in Google Scholar
Tian T, Zhang LQ, Ma XH, Zhou JN, Shen J. Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes 2012; 120: 217-23. 10.1055/s-0031-1297969TianTZhangLQMaXHZhouJNShenJ.Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysisExp Clin Endocrinol Diabetes20121202172310.1055/s-0031-129796922187293Open DOISearch in Google Scholar
Walter U, Kohlert T, Rahbari NN, Weitz J, Welsch T. Impact of preoperative diabetes on long-term survival after curative resection of pancreatic adenocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 2014; 21: 1082-9. 10.1245/s10434-013-3415-6WalterUKohlertTRahbariNNWeitzJWelschT.Impact of preoperative diabetes on long-term survival after curative resection of pancreatic adenocarcinoma: a systematic review and meta-analysisAnn Surg Oncol2014211082910.1245/s10434-013-3415-624322532Open DOISearch in Google Scholar
Wang YG, Wang P, Wang B, Fu ZJ, Zhao WJ, Yan SL. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2014; 9: e95485. 10.1371/journal.pone.0095485WangYGWangPWangBFuZJZhaoWJYanSLDiabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysisPLoS One20149e9548510.1371/journal.pone.0095485402258924830459Open DOISearch in Google Scholar
Cai H, Xu Z, Xu T, Yu B, Zou Q. Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res Rev 2015; 31: 336-43. 10.1002/dmrr.2582CaiHXuZXuTYuBZouQ.Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studiesDiabetes Metab Res Rev2015313364310.1002/dmrr.258225066306Open DOISearch in Google Scholar
Chen L, Li H, Gu L, Ma X, Li X, Gao Y, et al. The impact of diabetes mellitus on renal cell carcinoma prognosis: a meta-analysis of cohort studies. Medicine (Baltimore) 2015; 94: e1055. 10.1097/MD.0000000000001055ChenLLiHGuLMaXLiXGaoYet al.The impact of diabetes mellitus on renal cell carcinoma prognosis: a meta-analysis of cohort studiesMedicine (Baltimore)201594e105510.1097/MD.0000000000001055450460726131819Open DOISearch in Google Scholar
Jiamset I, Hanprasertpong J. Impact of diabetes mellitus on oncological outcomes after radical hysterectomy for early stage cervical cancer. J Gynecol Oncol 2016; 27: e28. 10.3802/jgo.2016.27.e28JiamsetIHanprasertpongJ.Impact of diabetes mellitus on oncological outcomes after radical hysterectomy for early stage cervical cancerJ Gynecol Oncol201627e2810.3802/jgo.2016.27.e28482335927029749Open DOISearch in Google Scholar
Inal A, Kaplan MA, Kucukoner M, Urakci Z, Kilinc F, Isikdogan A. Is diabetes mellitus a negative prognostic factor for the treatment of advanced nonsmall-cell lung cancer? Rev Port Pneumol 2014; 20: 62-8. 10.1016/J.rppneu.2013.09.001InalAKaplanMAKucukonerMUrakciZKilincFIsikdoganA.Is diabetes mellitus a negative prognostic factor for the treatment of advanced nonsmall-cell lung cancer?Rev Port Pneumol20142062810.1016/J.rppneu.2013.09.00124210228Open DOISearch in Google Scholar
Hatlen P, Gronberg BH, Langhammer A, Carlsen SM, Amundsen T. Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol 2011; 6: 1810-7. 10.1097/JTO.0b013e31822a75beHatlenPGronbergBHLanghammerACarlsenSMAmundsenT.Prolonged survival in patients with lung cancer with diabetes mellitusJ Thorac Oncol201161810710.1097/JTO.0b013e31822a75be21964531Open DOISearch in Google Scholar
Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Matsumoto S, et al. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer 2015; 15: 989. 10.1186/s12885-015-2012-4ImaiHKairaKMoriKOnoAAkamatsuHMatsumotoSet al.Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancerBMC Cancer20151598910.1186/s12885-015-2012-4468562626690494Open DOISearch in Google Scholar
Zhu L, Cao H, Zhang T, Shen H, Dong W, Wang L, et al. The effect of diabetes mellitus on lung cancer prognosis: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore) 2016; 95: e3528. 10.1097/MD.0000000000003528ZhuLCaoHZhangTShenHDongWWangLet al.The effect of diabetes mellitus on lung cancer prognosis: a PRISMA-compliant meta-analysis of cohort studiesMedicine (Baltimore)201695e352810.1097/ MD.0000000000003528499872527124062Open DOISearch in Google Scholar
Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 2013; 18: 1248-55. 10.1634/theoncologist.2013-0111YinMZhouJGorakEJQuddusF.Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysisOncologist20131812485510.1634/theoncologist.2013-0111386841724258613Open DOISearch in Google Scholar
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216. 10.1371/journal.pmed.1001216AltmanDGMcShaneLMSauerbreiWTaubeSE.Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaborationPLoS Med20129e100121610.1371/journal.pmed.1001216336208522675273Open DOISearch in Google Scholar
